Clinical Trial Update: Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the antibody response to 500 micrograms of G17DT in patients with gastric cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• G17DT

Snippet

Sponsor: Cancer Advances Inc. | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED